Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$65.26
-2.3%
$63.09
$42.52
$68.64
$133.21B0.2311.90 million shs3.80 million shs
Otsuka Holdings Co., Ltd. - Unsponsored ADR stock logo
OTSKY
Otsuka
$38.12
-0.9%
$36.52
$25.30
$40.92
$40.94B0.0238,394 shs13,662 shs
Pfizer Inc. stock logo
PFE
Pfizer
$27.99
-1.6%
$26.06
$23.58
$29.21
$159.51B0.3441.44 million shs16.44 million shs
Sanofi stock logo
SNY
Sanofi
$43.32
-2.1%
$43.93
$40.89
$52.68
$105.06B0.353.44 million shs1.41 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
0.00%-0.12%+3.44%+18.47%+41.98%
Otsuka Holdings Co., Ltd. - Unsponsored ADR stock logo
OTSKY
Otsuka
0.00%+0.98%-5.03%+20.43%+36.11%
Pfizer Inc. stock logo
PFE
Pfizer
0.00%-0.32%+6.43%+10.73%+14.34%
Sanofi stock logo
SNY
Sanofi
0.00%-0.27%+1.79%-1.10%-4.86%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$65.26
-2.3%
$63.09
$42.52
$68.64
$133.21B0.2311.90 million shs3.80 million shs
Otsuka Holdings Co., Ltd. - Unsponsored ADR stock logo
OTSKY
Otsuka
$38.12
-0.9%
$36.52
$25.30
$40.92
$40.94B0.0238,394 shs13,662 shs
Pfizer Inc. stock logo
PFE
Pfizer
$27.99
-1.6%
$26.06
$23.58
$29.21
$159.51B0.3441.44 million shs16.44 million shs
Sanofi stock logo
SNY
Sanofi
$43.32
-2.1%
$43.93
$40.89
$52.68
$105.06B0.353.44 million shs1.41 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
0.00%-0.12%+3.44%+18.47%+41.98%
Otsuka Holdings Co., Ltd. - Unsponsored ADR stock logo
OTSKY
Otsuka
0.00%+0.98%-5.03%+20.43%+36.11%
Pfizer Inc. stock logo
PFE
Pfizer
0.00%-0.32%+6.43%+10.73%+14.34%
Sanofi stock logo
SNY
Sanofi
0.00%-0.27%+1.79%-1.10%-4.86%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
2.56
Moderate Buy$66.061.22% Upside
Otsuka Holdings Co., Ltd. - Unsponsored ADR stock logo
OTSKY
Otsuka
2.00
HoldN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
2.19
Hold$28.281.05% Upside
Sanofi stock logo
SNY
Sanofi
2.40
Hold$49.5014.27% Upside

Current Analyst Ratings Breakdown

Latest OTSKY, PFE, BMY, and SNY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/31/2026
Pfizer Inc. stock logo
PFE
Pfizer
UpgradeHold (C-)Hold (C)
8/18/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
UpgradeHold (C+)Buy (B-)
8/17/2026
Pfizer Inc. stock logo
PFE
Pfizer
DowngradeHold (C)Hold (C-)
8/7/2026
Pfizer Inc. stock logo
PFE
Pfizer
Lower Price TargetBuy$35.00 ➝ $31.00
8/5/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Initiated CoverageMarket PerformStrong-Buy
8/5/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Initiated CoverageHoldBuy
8/5/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
DowngradeBuyNeutral
8/5/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
DowngradeBuyHold
8/5/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Initiated CoverageBuy$75.00
8/5/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
UpgradeMarket PerformOutperform
8/5/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Initiated CoverageOverweight
(Data available from 9/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$48.19B2.77$7.94 per share8.22$9.09 per share7.18
Otsuka Holdings Co., Ltd. - Unsponsored ADR stock logo
OTSKY
Otsuka
$16.51B2.48$2.96 per share12.88$19.33 per share1.97
Pfizer Inc. stock logo
PFE
Pfizer
$62.58B2.55$4.33 per share6.47$15.26 per share1.83
Sanofi stock logo
SNY
Sanofi
$49.35B2.13$6.92 per share6.26$33.27 per share1.30
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$7.05B$4.5414.3610.130.3218.87%66.90%14.74%10/29/2026 (Estimated)
Otsuka Holdings Co., Ltd. - Unsponsored ADR stock logo
OTSKY
Otsuka
$2.43B$2.4915.3116.222.7615.50%12.86%9.59%10/30/2026 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$7.77B$0.7636.829.521.916.80%19.63%8.46%11/3/2026 (Estimated)
Sanofi stock logo
SNY
Sanofi
$8.84B$1.9122.698.241.338.66%14.19%7.95%10/23/2026 (Estimated)

Latest OTSKY, PFE, BMY, and SNY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2026Q2 2026
Pfizer Inc. stock logo
PFE
Pfizer
$0.6820$0.77+$0.0880-$0.04$14.40 billion$15.03 billion
7/31/2026Q2 2026
Otsuka Holdings Co., Ltd. - Unsponsored ADR stock logo
OTSKY
Otsuka
$0.5060$0.70+$0.1940$0.70$3.95 billion$4.41 billion
7/30/2026Q2 2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$1.60$2.04+$0.44$1.62$11.74 billion$12.97 billion
7/30/2026Q2 2026
Sanofi stock logo
SNY
Sanofi
N/A$2.41N/A$0.17N/A$13.36 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$2.523.86%+1.61%55.51%17 Years
Otsuka Holdings Co., Ltd. - Unsponsored ADR stock logo
OTSKY
Otsuka
$0.130.34%N/A5.22%N/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.15%-13.20%226.32%16 Years
Sanofi stock logo
SNY
Sanofi
$1.764.06%+6.46%92.15%N/A

Latest OTSKY, PFE, BMY, and SNY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/24/2026
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.437.01%7/24/20267/24/20269/1/2026
6/17/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
quarterly$0.634.34%7/2/20267/2/20268/3/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
1.89
1.53
1.38
Otsuka Holdings Co., Ltd. - Unsponsored ADR stock logo
OTSKY
Otsuka
0.05
2.21
1.65
Pfizer Inc. stock logo
PFE
Pfizer
0.71
1.27
0.96
Sanofi stock logo
SNY
Sanofi
0.21
0.99
0.64

Institutional Ownership

CompanyInstitutional Ownership
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
76.41%
Otsuka Holdings Co., Ltd. - Unsponsored ADR stock logo
OTSKY
Otsuka
N/A
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Sanofi stock logo
SNY
Sanofi
14.03%

Insider Ownership

CompanyInsider Ownership
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
0.05%
Otsuka Holdings Co., Ltd. - Unsponsored ADR stock logo
OTSKY
Otsuka
N/A
Pfizer Inc. stock logo
PFE
Pfizer
0.62%
Sanofi stock logo
SNY
Sanofi
1.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
32,5002.04 billion2.04 billionOptionable
Otsuka Holdings Co., Ltd. - Unsponsored ADR stock logo
OTSKY
Otsuka
37,7581.07 billionN/ANot Optionable
Pfizer Inc. stock logo
PFE
Pfizer
75,0005.70 billion5.66 billionOptionable
Sanofi stock logo
SNY
Sanofi
74,8462.42 billion2.40 billionOptionable

Recent News About These Companies

Sanofi (NASDAQ:SNY) Upgraded at Wall Street Zen
Sanofi 2026 Q2 - Results - Earnings Call Presentation
Sanofi Says EU Expands MenQuadfi Approval
Press Release: Sanofi’s half-year financial report for 2026

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bristol Myers Squibb stock logo

Bristol Myers Squibb NYSE:BMY

$65.26 -1.56 (-2.33%)
As of 02:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Otsuka stock logo

Otsuka OTCMKTS:OTSKY

$38.12 -0.34 (-0.88%)
As of 01:41 PM Eastern

Otsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices. It also provides clinical testing, medical equipment, food products, cosmetics, functional food products, chemical products, soft drinks, beverages, analytical and measurement instruments, nutritional products, vehicle headlight testers, synthetic resin molded products, paper products, and insecticide and toiletry products. In addition, the company offers IT solution services; adhesive tapes; flaky titanate and compounds; IV solutions; infusion and clinical nutrition products; hydrazine; plant-based food products; reinsurance underwriting services; wine; stable isotopes; food supplements; urinary tract health products; software and services for management of mental healthcare systems; anticancer drugs; terracess; bio-pesticides; dietetic food products; spring and mineral water; and polyolefin foams. Further, it engages in the warehousing and transport, medical device operational management, shared service, environmental health management, and venture capital and incubation businesses; rental of medical devices and related products; purchase and sale of agricultural products; import and export trading business; tuberculosis research and development activities; manufacturing and development of xenotransplantation products; and processing and marketing of functional films, as well as planning, design, production, and construction of ceramic boards and arts, ceramic walls, reliefs, terracotta, ceramic OT and portraits, and ceramic sign boards; and operation of travel agency, and Hotel Ridge and California Table. Otsuka Holdings Co., Ltd. was founded in 1921 and is headquartered in Tokyo, Japan.

Pfizer stock logo

Pfizer NYSE:PFE

$27.98 -0.47 (-1.63%)
As of 02:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Sanofi stock logo

Sanofi NASDAQ:SNY

$43.32 -0.92 (-2.08%)
As of 02:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.